← Back to all trials
Completed
NCT01134575
CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)
Conditions: Acute Lymphoblastic Leukemia
Sex: All
Ages: 16 Years – N/A
Healthy volunteers: No
Phase: PHASE2
Enrollment: 90
Sponsor: M.D. Anderson Cancer Center
Location: University of Texas MD Anderson Cancer Center Houston Texas
Summary
The goal of this clinical research study is to learn if CMC-544 given alone, and possibly given in combination with rituximab, can help to control the disease in patients with ALL. The safety of the study drug(s) will also be studied.
Eligibility Criteria
Inclusion Criteria:
1. Previously treated ALL (including Burkitt's lymphoma and lymphoblastic lymphoma) in relapse or primary refractory. Patients in first relapse will be eligible regardless of the first remission duration. At least 10 patients in Salvage 1-2 will be treated to assess anti-ALL response more precisely.
2. Age 16 years or older. Pediatric patients (\
Source: ClinicalTrials.gov (NCT01134575). StuddyBuddy aggregates publicly available trial information.
